Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zeo ScientifiX, Inc.BPSR · Entity 8005 | Chief Science Officer | October 29, 2021 | November 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zeo ScientifiX, Inc.
Report date October 29, 2021 · Filed November 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,707,890 |
Ending reported balance
After 2021-10-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-10-29 · Other · Disposed 15,000,000 · Balance 101,707,890 F1: The shares of common stock of Organicell Regenerative Medicine, Inc., a Nevada corporation (the "Company") were disposed of and acquired, respectively, pursuant to an Exchange Agreement dated October 29, 2021 (the "Agreement"), whereby the Reporting Person exchanged shares of common stock of the Company previously issued under the Organicell Regenerative Medicine, Inc. Management and Consultants Performance Stock Plan for shares of common stock of the Company in the Organicell Regenerative Medicine, Inc. 2021 Equity Incentive Plan. The newly issued shares shall vest on December 31, 2023. F2: Received in exchange for the Company's common stock on a 1:1 basis. This exchange was completed in connection with the Agreement. Row 2 · 2021-10-29 · Other · Acquired 15,000,000 · Balance 116,707,890 F1: The shares of common stock of Organicell Regenerative Medicine, Inc., a Nevada corporation (the "Company") were disposed of and acquired, respectively, pursuant to an Exchange Agreement dated October 29, 2021 (the "Agreement"), whereby the Reporting Person exchanged shares of common stock of the Company previously issued under the Organicell Regenerative Medicine, Inc. Management and Consultants Performance Stock Plan for shares of common stock of the Company in the Organicell Regenerative Medicine, Inc. 2021 Equity Incentive Plan. The newly issued shares shall vest on December 31, 2023. F2: Received in exchange for the Company's common stock on a 1:1 basis. This exchange was completed in connection with the Agreement. |
| Common StockSEC Table I · non-derivative | IndirectAdditional shares held by spouse | 166,790,190 |
Reported balance
Holding disclosure · report date 2021-10-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 166,790,190 F3: The total number of shares of common stock owned collectively by Maria Ines Mitrani and Albert Mitrani is 283,498,080. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock of Organicell Regenerative Medicine, Inc., a Nevada corporation (the "Company") were disposed of and acquired, respectively, pursuant to an Exchange Agreement dated October 29, 2021 (the "Agreement"), whereby the Reporting Person exchanged shares of common stock of the Company previously issued under the Organicell Regenerative Medicine, Inc. Management and Consultants Performance Stock Plan for shares of common stock of the Company in the Organicell Regenerative Medicine, Inc. 2021 Equity Incentive Plan. The newly issued shares shall vest on December 31, 2023.
F2: Received in exchange for the Company's common stock on a 1:1 basis. This exchange was completed in connection with the Agreement.
F3: The total number of shares of common stock owned collectively by Maria Ines Mitrani and Albert Mitrani is 283,498,080.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2021 Filed May 7, 2021 21:45 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | SaleCommon Stock | 25,000 | $0.29 | $7,200.00 |
DisclosureSEC source: 0001683168-21-001825 · ownership.xml · nonDerivative · entry 2 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,675,000 Read SEC document |
| May 05, 2021 Filed May 7, 2021 21:45 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | SaleCommon Stock | 50,000 | $0.30 | $15,150.00 |
DisclosureSEC source: 0001683168-21-001825 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,700,000 Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:29 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | SaleCommon Stock | 50,000 | $0.41 | $20,250.00 |
DisclosureSEC source: 0001683168-21-001790 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,750,000 Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 21:45 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | SaleCommon Stock | 50,000 | $0.47 | $23,600.00 |
DisclosureSEC source: 0001683168-21-001702 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,800,000 Read SEC document |
| April 06, 2021 Filed Apr 14, 2021 16:30 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 5,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-001398 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Board approved Management and Consultant Performance Plan. F2 · price: The closing trading price of the stock on the date of the grant was $0.065 per share. Read SEC document |
| February 10, 2021 Filed Feb 22, 2021 19:47 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 5,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-000669 · ownership.xml · nonDerivative · entry 2 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Board approved Management and Consultant Performance Plan. F4 · price: The closing trading price of the stock on the date of the grant was $0.1075 per share. Read SEC document |
| January 27, 2021 Filed Feb 22, 2021 19:47 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 5,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-000669 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Board approved Management and Consultant Performance Plan. F3 · price: The closing trading price of the stock on the date of the grant was $0.086 per share. Read SEC document |
| December 21, 2020 Filed Dec 30, 2020 16:49 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 15,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-20-004486 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,850,000 F1 · shares: Board approved bonus grant of shares F3 · price: The closing trading price of the stock on the date of the grant was $0.12 per share. Read SEC document |
| September 23, 2020 Filed Sep 30, 2020 16:03 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 7,000,000 | $0.28 | $1,960,000.00 |
DisclosureSEC source: 0001683168-20-003315 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Management and Consultant Performance Plan. Read SEC document |
| September 17, 2020 Filed Dec 9, 2020 18:51 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 5,000,000 | $0.03 | $135,000.00 |
DisclosureSEC source: 0001683168-20-004231 · ownership.xml · nonDerivative · entry 3 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Management and Consultant Performance Plan. Read SEC document |
| September 03, 2020 Filed Dec 9, 2020 18:51 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 5,000,000 | $0.03 | $135,000.00 |
DisclosureSEC source: 0001683168-20-004231 · ownership.xml · nonDerivative · entry 2 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Management and Consultant Performance Plan. Read SEC document |
| August 27, 2020 Filed Sep 18, 2020 17:05 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 15,000,000 | $0.18 | $2,685,000.00 |
DisclosureSEC source: 0001683168-20-003200 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Management and Consulant Performance Plan. Read SEC document |
| August 25, 2020 Filed Dec 9, 2020 18:51 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 5,000,000 | $0.03 | $135,000.00 |
DisclosureSEC source: 0001683168-20-004231 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Management and Consultant Performance Plan. Read SEC document |
| May 29, 2020 Filed Aug 6, 2020 17:55 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 5,000,000 | $0.09 | $425,000.00 |
DisclosureSEC source: 0001683168-20-002555 · ownership.xml · nonDerivative · entry 3 MITRANI MARIA INES · CIK 0001690319 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Management and Consulant Performance Plan. Read SEC document |
| May 15, 2020 Filed Aug 6, 2020 17:55 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 10,000,000 | $0.04 | $400,000.00 |
DisclosureSEC source: 0001683168-20-002555 · ownership.xml · nonDerivative · entry 2 MITRANI MARIA INES · CIK 0001690319 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Management and Consulant Performance Plan. Read SEC document |
| May 01, 2020 Filed Aug 6, 2020 17:55 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 13,000,000 | $0.03 | $403,000.00 |
DisclosureSEC source: 0001683168-20-002555 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,850,000 F1 · shares: The shares were awarded pursuant to the Issuer's Management and Consulant Performance Plan. Read SEC document |
| April 23, 2018 Filed Aug 8, 2018 15:53 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | OtherWarrant · Derivative | 23,850,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001683168-18-002192 · ownership.xml · derivative · entry 2 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,757,985 shares Expires 2027-03-08 F1 · security: Cashless exercise pursuant to Plan and Agreement of Reorginzation filed with Issuer's Form 8-K dated April 23, 2018. Read SEC document |
| April 23, 2018 Filed Aug 8, 2018 15:53 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantCommon Stock | 2,092,105 | $0.00 | $2,092.11 |
DisclosureSEC source: 0001683168-18-002192 · ownership.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,850,000 Read SEC document |
| March 08, 2017 Filed Mar 13, 2017 18:15 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantWarrant (right to purchase) · Derivative | 13,850,000 | $0.00 Strike: $0.02 | $0.00 |
DisclosureSEC source: 0001690348-17-000002 · primary_doc.xml · derivative · entry 3 MITRANI MARIA INES · CIK 0001690319 · Director · VP, Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,850,000 Underlying: Common Stock · 13,850,000 shares Expires 2027-03-08 F1 · derivative.exercise_price: Exercisable on a cash or "cashless" basis. Read SEC document |
| March 08, 2017 Filed Mar 13, 2017 18:15 UTC | Zeo ScientifiX, Inc. BPSR · Entity 8005 | GrantSeries A Non-Convertible Preferred Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001690348-17-000002 · primary_doc.xml · nonDerivative · entry 1 MITRANI MARIA INES · CIK 0001690319 · Director · VP, Chief Science Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.